Legend Biotech
Piscataway
About Legend Biotech
Legend Biotech is a clinical-stage biopharmaceutical company that discovers and develops novel cell therapies for oncology. The company develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Its initial product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $500K – $1M
- Total funding: $750.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2023)
- Ticker: nasdaq:LEGN
- Website: legendbiotech.com
- Phone: +1.732.317.5050
Industries & Categories
Biotechnology, Health Care, Life Science, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/legend-biotech-26450 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.